SGI
ALNY icon

Summit Global Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Summit Global Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,145
Closed -$849K – 462
2025
Q1 		$849K Buy
+3,145
New +$808K 0.06% 192

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Summit Global Investments's ALNY Position: Q2 2025 in Review

Summit Global Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 3,145 shares — an estimated $849K sold.

Summit Global Investments first reported a position in ALNY in Q1 2025 and held it in 1 quarter. The position peaked at $849K in Q1 2025. 653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Summit Global Investments reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Summit Global Investments sold 3,145 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $849K.
  • Summit Global Investments first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Summit Global Investments's Alnylam Pharmaceuticals position peaked at $849K in Q1 2025.
  • 653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Summit Global Investments's 13F filing for Q2 2025, filed 12 Aug 2025.